Summary of Key Information:

Reporting Period (Quarter/Year): Quarter and financial year ended March 31, 2026

Nature of Filing / Announcement: Outcome of Board Meeting and Financial Results

Date of Board Meeting / Approval: May 27, 2026

Audit Opinion: Unmodified Opinion

Auditor's Comment: Statutory Auditors issued reports with unmodified opinion on both standalone and consolidated financial results

Key Financial Highlights [Rs. in lakhs]

Standalone Results:

Revenue from Operations:

  • Q4 FY26: ₹56,436.37 (vs ₹48,200.43 in Q4 FY25)
  • FY26: ₹212,632.72 (vs ₹207,011.19 in FY25) - 2.7% YoY growth

Total Income:

  • Q4 FY26: ₹61,152.80
  • FY26: ₹223,732.78 (vs ₹217,563.03 in FY25)

Net Profit:

  • Q4 FY26: ₹10,707.03
  • FY26: ₹28,592.34 (vs ₹27,362.60 in FY25) - 4.5% YoY growth

EPS:

  • Q4 FY26: ₹6.58
  • FY26: ₹17.56 (vs ₹16.81 in FY25)

Other Equity: ₹247,635.75 (vs ₹227,090.89 in FY25)

Cash and Cash Equivalents: ₹3,746.70

Debt: Not specifically disclosed in breakdown

Consolidated Results:

Revenue from Operations:

  • Q4 FY26: ₹58,478.71
  • FY26: ₹217,003.32 (vs ₹210,812.04 in FY25) - 2.9% YoY growth

Total Income:

  • Q4 FY26: ₹63,467.79
  • FY26: ₹228,445.15 (vs ₹219,878.12 in FY25)

Net Profit:

  • Q4 FY26: ₹10,339.67
  • FY26: ₹28,142.16 (vs ₹26,678.81 in FY25) - 5.5% YoY growth

EPS:

  • Q4 FY26: ₹6.35
  • FY26: ₹17.29 (vs ₹16.39 in FY25)

Other Equity: ₹246,883.10 (vs ₹226,479.95 in FY25)

Cash and Cash Equivalents: ₹4,867.81

Segment-wise Performance:

The Company has only one segment of activity namely "Pharmaceuticals"

Corporate Actions:

Dividend: Interim dividend of ₹5/- per equity share of face value ₹1/- each for FY25-26 was approved on February 5, 2026

Other Significant Information:

Fair Value Adjustments:

  • Recognized fair value loss of ₹1,329.75 lakhs under other expenses in Q4 FY26
  • Net fair value gain of ₹1,179.23 lakhs recorded under other income for FY26

Subsidiaries: Consolidated results include:

1. FDC International Limited (UK)

2. FDC Inc. (USA)

3. Fair Deal Corporation Pharmaceuticals SA (Pty) Ltd (South Africa)

Board Meeting Duration: Commenced at 12:30 p.m. and concluded at 02:55 p.m.